Retrospective Analysis of Efficacy and Safety of Tocilizumab Treatment in Patients with Severe Systemic-Onset Juvenile Idiopathic Arthritis Followed for 12 Months

Table 3

Characteristics of background therapy in patients with sJIA at the moment of enrollment in the study.

Drug	Dose (median (25; 75))	Number of children
Methotrexate, mg/m^2/week	19 (15; 24)	17
Prednisolone, mg/day +	8.7 (6.3; 12)
Methotrexate, mg/m^2/week	19 (15;23)	11
Methotrexate, mg/m^2/week +	17 (15; 23)
Cyclosporine, mg/kg/day	4 (4; 4)	14
Prednisolone, mg/day +	9.5 (6.5; 12)
Methotrexate, mg/m^2/week +	17 (15; 23)
Cyclosporine, mg/kg/day	4 (4; 4)	33
NSAIDs	—	75